Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination

Johnson M. et al, (2021), Frontiers in Tropical Diseases, 2

Feasibility and acceptability of targeted salivary cytomegalovirus screening through universal newborn hearing screening

Webb E. et al, (2021), Journal of Paediatrics and Child Health

Willingness of children and adolescents to have a COVID-19 vaccination: results of a large whole schools survey in England

FAZEL M. et al, (2021), E Clinical Medicine

Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.

Shrestha S. et al, (2021), J Infect Dis, 224, S267 - S274

Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.

Lin G-L. et al, (2021), Nat Commun, 12

A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data.

Phillips MT. et al, (2021), Stat Med

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.

Madhi SA. et al, (2021), Lancet HIV

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nat Commun, 12

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nature communications, 12

Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.

Qadri F. et al, (2021), Lancet

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Liu X. et al, (2021), Lancet

Host gene signature shows promise to distinguish bacterial and viral infections.

Channon-Wells S. and O'Connor D., (2021), Lancet Digit Health, 3, e465 - e466

Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK

Kadambari S. and Vanderslott S., (2021), The Lancet Infectious Diseases

A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies

Nijman RG. et al, (2021), Frontiers in Pediatrics, 9

Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine

Payne R. et al, (2021)

Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.

Gurung M. et al, (2021), Pediatr Infect Dis J

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial

Clemens SC. et al, (2021)

"Should children be offered covid-19 vaccination?" No

Wilkinson D. et al, (2021), BMJ: British Medical Journal

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Liu X. et al, (2021), SSRN Electronic Journal

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Flaxman A. et al, (2021), SSRN Electronic Journal

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?